Gelatin-based delivery systems for cancer gene therapy cancer gene therapy

Journal of Drug Targeting

Volumn 17, Issue 10, 2009, Pages 731-738

  Nezhadi, Somayeh Hallaj ^a   Choong, Peter F M ^b,c   Lotfipour, Farzaneh ^a,d   Dass, Crispin R ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Gelatin; Gene therapy; Plasmid; Tumor; Viral vector

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; GELATIN; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMID DNA; POLYMER; SCATTER FACTOR; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VIRUS VECTOR;

BREAST ADENOCARCINOMA; CANCER GENE THERAPY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANIMALS; DNA; GELATIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; PLASMIDS;

EID: 70350754529     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903096540     Document Type: Review

References (50)

1. Alain Rolland SMS. (2003). Pharmaceutical Gene Delivery Systems. New York: Marcel Dekker.
2. Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM. (2007). Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol, 171(4), 1079-1088.
3. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Hearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. (1995). T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science, 270(5235), 475-480.
4. Brown MD, Schatzlein AG, Uchegbu IF. (2001). Gene delivery with synthetic (non viral) carriers. Int J Pharm, 229(1-2), 1-21.
5. Coester CJ, Langer K, van Briesen H, Kreuter J. (2000). Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul, 17(2), 187-193.
6. Dang JM, Leong KW. (2006). Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev, 58(4), 487-499.
7. Davis ME. (2002). Non-viral gene delivery systems. Curr Opin Biotechnol, 13(2), 128-131.
8. Digenis GA, Gold TB, Shah VP. (1994). Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci, 83(7), 915-921.
9. Domb AJ, Kost J, Wiseman DM. (1997). Handbook of Biodegradable Polymers. Boca Raton, FL: CRC Press, Taylor & Francis Group.
10. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. (2004). Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med, 6(6), 597-602.
11. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. (2002). Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J Control Release, 80(1-3), 333-343.
12. Gao X, Huang L. (1996). Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry, 35(3), 1027-1036.
13. Gene Therapy Clinical Trials Worldwide. (2009). http://www.wiley. co.uk/genetherapy/clinical/. Last accessed May 4, 2009.
14. Gómez-Estaca J, Monteroa P, Fernández-Martín F, Gómez-Guillén MC. (2009). Physico-chemical and film-forming properties of bovine-hide and tuna-skin gelatin: A comparative study. J Food Process Eng, 90, 480-486.
15. Gorecki DC. (2001). Prospects and problems of gene therapy: An update. Expert Opin Emerg Drugs, 6(2), 187-198.
16. Habib NA. (2000). Cancer Gene Therapy: Past Achievements and Future Challenges. New York: Kluwer Academic Publishers.
17. Hunter AC. (2006). Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev, 58(14), 1523-1531.
18. Igor Galaev BM. (2008). Smart Polymers Applications in Biotechnology and Biomedicine. Boca Raton, FL: CRC Press, Taylor & Francis Group.
19. Imeson A. (1997). Thickening and Gelling Agents for Food. 2nd ed. London: Blackie Academic and Professional.
20. Isobe H, Sugiyama S, Fukui Ki, Iwasawa Y, Nakamura E. (2001). Atomic force microscope studies on condensation of plasmid DNA with functionalized fullerenes. This research was supported by Grant-in-Aid for Specially Promoted Research from Ministry of Education, Culture, Sports, Science, and Technology. Angew Chem Int Ed Engl, 40(18), 3364-3367.
21. Karim AA, Bhat R. (2009). Fish gelatin: Properties, challenges, and prospects as an alternative to mammalian gelatins. Food Hydrocolloids, 23, 563-576.
22. Kaul G, Amiji M. (2002). Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res, 19(7), 1061-1067.
23. Kommareddy S, Amiji M. (2007). Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther, 14(5), 488-498.
24. Kuo PY, Saltzman WM. (1996). Novel systems for controlled delivery of macromolecules. Crit Rev Eukaryot Gene Expr, 6(1), 59-73.
25. Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. (2004a). Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther, 11(15), 1205-1214. (Pubitemid 39136784)
26. Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. (2004b). Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res, 21(7), 1109-1118.
27. Leaf Huang M-CH, Wagner E. (2005). Non-Viral Vectors for Gene Therapy. Vol.1, 2nd ed. San Diego, CA: Elsevier Inc.
28. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. (2004). Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: Strategies to improve transfection effi -cacy. Eur J Pharm Biopharm, 57(1), 1-8.
29. Marty JJ, Oppenheimer RC, Speiser P. (1978). Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv, 53(1), 17-23.
30. Matsumoto G, Kushibiki T, Kinoshita Y, Lee U, Omi Y, Kubota E, Tabata Y. (2006). Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci, 97(4), 313-321.
31. McTaggart S, Al-Rubeai M. (2002). Retroviral vectors for human gene delivery. Biotechnol Adv, 20(1), 1-31.
32. Mumper RJ, Duguid JG, Anwer K, Barron MK, Nitta H, Rolland AP. (1996). Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm Res, 13(5), 701-709.
33. Park BH, Lee JH, Jeong JS, Rha SH, Kim SE, Kim JS, Kim JM, Hwang TH. (2005). Vascular administration of adenoviral vector soaked in absorbable gelatin sponge particles (GSP) prolongs the transgene expression in hepatocytes. Cancer Gene Ther, 12(2), 116-121.
34. Park TG, Jeong JH, Kim SW. (2006). Current status of polymeric gene delivery systems. Adv Drug Deliv Rev, 58(4), 467-486.
35. Patil SD, Rhodes DG, Burgess DJ. (2005). DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS J, 7(1), E61-E77.
36. Scheffel U, Rhodes BA, Natarajan TK, Wagner HN Jr. (1972). Albumin microspheres for study of the reticuloendothelial system. J Nucl Med, 13(7), 498-503.
37. Schmidt-Wolf GD, Schmidt-Wolf IG. (2003). Non-viral and hybrid vectors in human gene therapy: An update. Trends Mol Med, 9(2), 67-72.
38. Swarbrick J. (2007). Encyclopedia of Pharmaceutical Technology. 3rd ed. New York: Informa Healthcare USA, Inc.
39. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni, SD, Kadmon D, Thompson TC. (2008). Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis, [Epub ahead of print].
40. Taira K, Kataoka, K, Niidome T. (eds.). (2005). Non-Viral Gene Therapy Gene Design and Delivery. Tokyo: Springer-Verlag Tokyo.
41. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y. (2008). Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther, 7(7), 1864-1870.
42. Truong-Le VL, August JT, Leong KW. (1998). Controlled gene delivery by DNA-gelatin nanospheres. Hum Gene Ther, 9(12), 1709-1717.
43. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August JT, Leong KW. (1999). Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys, 361(1), 47-56.
44. United States Pharmacopeia (USP 31, NF 26). (2008). Baltimore: Port City Press.
45. Vorburger SA, Hunt KK. (2002). Adenoviral gene therapy. Oncologist, 7(1), 46-59.
46. Weir B, Zhao X, Meyerson M. (2004). Somatic alterations in the human cancer genome. Cancer Cell, 6(5), 433-438.
47. Yamamoto M, Ikada Y, Tabata Y. (2001). Controlled release of growth factors based on biodegradation of gelatin hydrogel. J Biomater Sci Polym Ed, 12(1), 77-88. (Pubitemid 32331415)
48. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem, 270(32), 18997-19007.
49. Zhang X, Godbey WT. (2006). Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev, 58(4), 515-534. (Pubitemid 43928170)
50. Zwiorek K, Kloeckner J, Wagner E, Coester C. (2005). Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharm Sci, 7(4), 22-28.